Skip to content

Kanagawa Intravenous and Endvascular Treatment Registry

Kanagawa Intravenous and Endovascular Treatment Registry for Acute Ischemic Stroke

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05213533
Acronym
K-NET
Enrollment
4000
Registered
2022-01-28
Start date
2018-01-01
Completion date
2022-10-31
Last updated
2022-02-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Ischemic Stroke

Keywords

acute stroke, mechanical thrombectomy, intravenous tPA

Brief summary

The K-NET registry is a prospective, multicenter, observational registry study for all consecutive patients who received intravenous tPA therapy and/or endovascular treatment for acute ischemic stroke. This study is attended by 40 of the 58 Primary Stroke Centers in Kanagawa Prefecture, which is located in the Tokyo metropolitan area and has a population of 9.24 million. Patient enrollment for this study began in January 2018.

Detailed description

Inclusion criteria for this study are all consecutive patients who meet either or both of the patients who received intravenous tPA therapy for acute ischemic stroke and intention to perform EVT for large vessel occlusion. There were no exclusion criteria. The local neurologists, neurosurgeons, and neurointerventionalists at each institution made the decision to perform EVT and intravenous tPA. The primary outcome was good as defined by the modified Rankin Scale (mRS) of 0 to 2 at three months. We also determined a favorable outcome: mRS 0-2 or not worsening of the mRS score at three months. Secondary analyses included predicting a favorable outcome using multivariate logistic regression analysis.

Interventions

None listed

Sponsors

St. Marianna University Toyoko Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

Inclusion criteria for this study are all consecutive patients who meet either or both of the patients who received intravenous tPA therapy for acute ischemic stroke and intention to perform EVT for large vessel occlusion.

Exclusion criteria

There were no

Design outcomes

Primary

MeasureTime frameDescription
modified Rankin Scaleafter 3 monthsThe Modified Rankin Score (mRS) is a 6 point disability scale with possible scores ranging from 0 to 6. This is the most widely used outcome measure in stroke clinical trials. Standardized interviews to obtain a mRS score are recommended at 3 months following hospital discharge. 0 The patient has no residual symptoms. 1. The patient has no significant disability; able to carry out all pre-stroke activities. 2. The patient has slight disability; unable to carry out all pre-stroke activities but able to look after self without daily help. 3. The patient has moderate disability; requiring some external help but able to walk without the assistance of another individual. 4. The patient has moderately severe disability; unable to walk or attend to bodily functions without assistance of another individual. 5. The patient has severe disability; bedridden, incontinent, requires continuous care. 6. The patient has expired.

Countries

Japan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026